Cardiovascular disease event rates in patients with severe psoriasis treated with systemic anti‐inflammatory drugs: a Danish real‐world cohort study

Psoriasis is a chronic inflammatory disorder associated with cardiovascular morbidity and mortality. Systemic anti‐inflammatory drugs, including biological agents, are widely used in the treatment of patients with moderate to severe psoriasis and may attenuate the risk of cardiovascular disease events. We therefore examined the rate of cardiovascular disease events in patients with severe psoriasis treated with systemic anti‐inflammatory drugs.

[1]  W. Boehncke,et al.  The ‘psoriatic march’: a concept of how severe psoriasis may drive cardiovascular comorbidity , 2011, Experimental dermatology.

[2]  C. Lang,et al.  More than skin deep: atherosclerosis as a systemic manifestation of psoriasis , 2009, The British journal of dermatology.

[3]  Andrea B Troxel,et al.  Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. , 2010, European heart journal.

[4]  A. Kyrgidis,et al.  Biologic therapies for chronic plaque psoriasis and cardiovascular events. , 2011, JAMA.

[5]  M. Hochberg,et al.  Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis , 2010, Annals of the rheumatic diseases.

[6]  L. Jacobsson,et al.  Treatment with tumor necrosis factor inhibitors and the risk of acute coronary syndromes in early rheumatoid arthritis. , 2012, Arthritis and rheumatism.

[7]  W. Dixon,et al.  What effects might anti-TNFα treatment be expected to have on cardiovascular morbidity and mortality in rheumatoid arthritis? A review of the role of TNFα in cardiovascular pathophysiology , 2007, Annals of the rheumatic diseases.

[8]  E. Coomes,et al.  Methotrexate in Atherogenesis and Cholesterol Metabolism , 2011, Cholesterol.

[9]  R. Stern,et al.  Going beyond associative studies of psoriasis and cardiovascular disease. , 2012, The Journal of investigative dermatology.

[10]  L. Skov,et al.  Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study , 2011, Journal of Internal Medicine.

[11]  Timothy L Lash,et al.  The predictive value of ICD-10 diagnostic coding used to assess Charlson comorbidity index conditions in the population-based Danish National Registry of Patients , 2011, BMC medical research methodology.

[12]  A. Menter,et al.  Exploring the association between cardiovascular and other disease‐related risk factors in the psoriasis population: the need for increased understanding across the medical community , 2010, Journal of the European Academy of Dermatology and Venereology : JEADV.

[13]  A. Troxel,et al.  The risk of stroke in patients with psoriasis. , 2009, The Journal of investigative dermatology.

[14]  A. Kimball,et al.  The effect of systemic psoriasis therapies on the incidence of myocardial infarction: a cohort study , 2011, The British journal of dermatology.

[15]  R. Kirsner,et al.  Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. , 2005, Journal of the American Academy of Dermatology.

[16]  Hisashi Adachi,et al.  Inflammation, atherosclerosis, and coronary artery disease. , 2005, The New England journal of medicine.

[17]  S. Pocock,et al.  The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. , 2007, Preventive medicine.

[18]  L. Skov,et al.  Psoriasis Carries an Increased Risk of Venous Thromboembolism: A Danish Nationwide Cohort Study , 2011, PloS one.

[19]  A. Menter,et al.  Current and future management of psoriasis , 2007, The Lancet.

[20]  D. Federman,et al.  Association of psoriasis with coronary artery, cerebrovascular, and peripheral vascular diseases and mortality. , 2009, Archives of dermatology.

[21]  D. Mozaffarian,et al.  Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. , 2011, The American journal of cardiology.

[22]  P. Ridker,et al.  AJC editor's consensus: psoriasis and coronary artery disease. , 2008, The American journal of cardiology.

[23]  S. Schneeweiss,et al.  Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. , 2011, JAMA.

[24]  P. Kiely,et al.  The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. , 2010, Rheumatology.

[25]  Frits Mastik,et al.  Effects of the Direct Lipoprotein-Associated Phospholipase A2 Inhibitor Darapladib on Human Coronary Atherosclerotic Plaque , 2008, Circulation.

[26]  J. Tu,et al.  ICD-10 adaptations of the Ontario acute myocardial infarction mortality prediction rules performed as well as the original versions. , 2007, Journal of clinical epidemiology.

[27]  M. Osler,et al.  The validity of the diagnosis of acute myocardial infarction in routine statistics: a comparison of mortality and hospital discharge data with the Danish MONICA registry. , 2003, Journal of clinical epidemiology.

[28]  B. Strober,et al.  Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. , 2011, JAMA.

[29]  Paul M Ridker,et al.  Inflammation in atherosclerosis: from pathophysiology to practice. , 2009, Journal of the American College of Cardiology.

[30]  L. Skov,et al.  Psoriasis and risk of atrial fibrillation and ischaemic stroke: a Danish Nationwide Cohort Study. , 2011, European heart journal.

[31]  Frank O. Nestle,et al.  Mechanisms of Disease: Psoriasis. , 2009 .

[32]  L. Skov,et al.  Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris , 2011, The British journal of dermatology.

[33]  E. Berardesca,et al.  Effective Therapy with Anti‐TNF‐α in Patients with Psoriatic Arthritis Is Associated with Decreased Levels of Metalloproteinases and Angiogenic Cytokines in the Sera and Skin Lesions , 2007, Annals of the New York Academy of Sciences.

[34]  F. Granath,et al.  Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients , 2003, European Journal of Epidemiology.

[35]  G. Mazzoccoli,et al.  Anti-tumor necrosis factor-α therapy and changes of flow-mediated vasodilatation in psoriatic and rheumatoid arthritis patients , 2010, Internal and emergency medicine.

[36]  E. Sijbrands,et al.  Unfavorable cardiovascular risk profiles in untreated and treated psoriasis patients. , 2007, Atherosclerosis.

[37]  M. Quinn,et al.  Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. , 2011, Rheumatology.

[38]  T. Truelsen,et al.  Validity of Stroke Diagnoses in a National Register of Patients , 2007, Neuroepidemiology.

[39]  Daniel B. Shin,et al.  Risk of myocardial infarction in patients with psoriasis. , 2006, JAMA.

[40]  L. Skov,et al.  Prognosis following first‐time myocardial infarction in patients with psoriasis: a Danish nationwide cohort study , 2011, Journal of internal medicine.

[41]  P. Ridker Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT) , 2009, Journal of thrombosis and haemostasis : JTH.